Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells

a Chemical structures of RG7112 and AMG232. b, c Cell numbers of U373MG, LN18, U251MG, A1207, DBTRG-05MG, and U87MG cells treated with different concentrations (0.07–54？μM) of RG7112 or AMG232 for 72？h were evaluated by quantifying image-based cell counting. Nonlinear regression analyses of dose？response curves are shown (n？=？3). Error bars represent standard deviation (SD). d The IC50 values obtained from dose？response curves are shown. Each bars represent mean (n？=？3) and 95% confidence interval (CI). e IC50 values of TP53 mutant cell lines (n？=？3) and TP53 wild-type cell lines (n？=？3) to RG7112 and AMG232 are shown. Data represent the mean and SD error (*p？<？0.01). f An image-based immunofluorescence assay for p21 (green), p53 (red) and DAPI (blue) in A1207 cells treated with DMSO, RG7112 (2？μM), AMG232 (2？μM), and Camptothecin (10？μM) for 72？h are shown. g p21 fluorescence intensity measurements for A1207 cells treated with increasing concentrations of RG7112 or AMG232 for 72？h are shown. The Z-factor for 18？μM RG7112 and 18？μM AMG232 in A1207 cells are indicated. h The mean percentage of p21-positive cells (n？=？3, SD) for six glioblastoma cell lines treated with DMSO, RG7112 (2？μM), AMG232 (2？μM) for 72？h are show